Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tianjin Pharmaceutical Da Ren Tang GroupSTU:2TZ 69 5-Year Yield-on-Cost % is 147.30 as of Aug. 05, 2026, which is 1501% above its 10-year median of 9.20. GuruFocus rates STU:2TZ with a GF Score™ of 69/100 and a GF Value™ of €1.65 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 514 Drug Manufacturers companies, Tianjin Pharmaceutical Da Ren Tang Group ranks better than 99.03% on this metric.
STU:2TZ's 5-Year Yield-on-Cost % is ranked better than 99.03% of 514
companies
in the Drug Manufacturers industry
Industry Median: 2.355
vs STU:2TZ: 147.30
Tianjin Pharmaceutical Da Ren Tang Group (STU:2TZ) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Tianjin Pharmaceutical Da Ren Tang Group 5-Year Yield-on-Cost % Related Terms
STU:2TZ vs ZTS: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Tianjin Pharmaceutical Da Ren Tang Group's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tianjin Pharmaceutical Da Ren Tang Group 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Tianjin Pharmaceutical Da Ren Tang Group's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Tianjin Pharmaceutical Da Ren Tang Group's 5-Year Yield-on-Cost % falls into.
Tianjin Pharmaceutical Da Ren Tang Group 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
What does a 5-Year Yield-on-Cost % of 147.30 mean?
Tianjin Pharmaceutical Da Ren Tang Group (STU:2TZ) has a 5-Year Yield-on-Cost % of 147.30 as of Aug. 05, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Tianjin Pharmaceutical Da Ren Tang Group and its competitors. This is 1501% above median its historical median of 9.20. Over the past decade, Tianjin Pharmaceutical Da Ren Tang Group's 5-Year Yield-on-Cost % has ranged from 4.13 to 147.30. According to the industry distribution chart, Tianjin Pharmaceutical Da Ren Tang Group ranks #5 out of 514 companies in the Drug Manufacturers industry, placing it in the top 1%.
Is Tianjin Pharmaceutical Da Ren Tang Group's 5-Year Yield-on-Cost % too high?
Tianjin Pharmaceutical Da Ren Tang Group's current 5-Year Yield-on-Cost % of 147.30 is 1501% above median its 10-year median of 9.20. Over the past 10 years, this metric has ranged from a low of 4.13 to a high of 147.30. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.36. Tianjin Pharmaceutical Da Ren Tang Group's value of 147.30 is 6154.8% above this industry median. Based on the distribution chart, Tianjin Pharmaceutical Da Ren Tang Group ranks #5 out of 514 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Tianjin Pharmaceutical Da Ren Tang Group has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tianjin Pharmaceutical Da Ren Tang Group's 5-Year Yield-on-Cost % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Tianjin Pharmaceutical Da Ren Tang Group ranks #5 out of 514 companies for 5-Year Yield-on-Cost %. This places Tianjin Pharmaceutical Da Ren Tang Group in the top 1% of its industry — outperforming the majority of peers. The industry median 5-Year Yield-on-Cost % is 2.36. Tianjin Pharmaceutical Da Ren Tang Group's value of 147.30 is 6154.8% above this benchmark. Historically, Tianjin Pharmaceutical Da Ren Tang Group's own 5-Year Yield-on-Cost % has ranged from 4.13 to 147.30 over the past decade. While the company's 10-year median is 9.20 vs. the industry median of 2.36, Tianjin Pharmaceutical Da Ren Tang Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.36, based on 514 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tianjin Pharmaceutical Da Ren Tang Group's current 5-Year Yield-on-Cost % of 147.30 is 6154.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Tianjin Pharmaceutical Da Ren Tang Group and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tianjin Pharmaceutical Da Ren Tang Group's current 5-Year Yield-on-Cost % is 147.30, which is 1501% above median its own 10-year median of 9.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tianjin Pharmaceutical Da Ren Tang Group stock overvalued right now?
Based on GuruFocus' analysis, Tianjin Pharmaceutical Da Ren Tang Group (STU:2TZ) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.65, compared to a current price of €2.40 — trading 45.5% above its estimated fair value. The current 5-Year Yield-on-Cost % is 147.30, which is 1501% above median its 10-year median of 9.20 and 6154.8% above the Drug Manufacturers industry median of 2.36. Tianjin Pharmaceutical Da Ren Tang Group's overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Tianjin Pharmaceutical Da Ren Tang Group (STU:2TZ), the current 5-Year Yield-on-Cost % is 147.30 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tianjin Pharmaceutical Da Ren Tang Group (STU:2TZ) Overvalued in 2026?
Based on GuruFocus' analysis, Tianjin Pharmaceutical Da Ren Tang Group stock appears to be overvalued.
The current stock price of €2.40 is trading 45.5% above its estimated GF Value™ of €1.65.
GuruFocus considers Tianjin Pharmaceutical Da Ren Tang Group to be Significantly Overvalued.
Key valuation signals for STU:2TZ:
5-Year Yield-on-Cost %: 147.30 (1501% above median its 10-year median of 9.20)
GF Value™: €1.65 vs. price of €2.40 (45.5% above fair value)
Industry Position: 6154.8% above the Drug Manufacturers median (#5 of 514)
No single metric tells the full story. See the STU:2TZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd is a pharmaceutical manufacturing company. The company is engaged in the production and sale of traditional Chinese medicine, Western medicine, healthcare products, and investment holding. It operates in two segments, namely the Chinese Medicine segment and the Western Medicine segment. The Chinese Medicine segment manufactures Chinese pharmaceutical products under brands owned by the group. The Western Medicine segment manufactures Western pharmaceutical products through cooperation with foreign companies. The company earns the majority of its revenue from the sale of Chinese medicine.
69GF Score
Get the complete analysis for STU:2TZ
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2TZ has been successfully added to your 
